Results 31 to 40 of about 2,607 (202)

Production of Neoepitopes by Dynamic Structural Changes on BP180/Type XVII Collagen [PDF]

open access: yesJournal of Investigative Dermatology, 2017
Linear IgA bullous dermatosis is characterized by IgA autoantibodies reactive with LAD-1 and LABD97, truncated forms of BP180 (type XVII collagen), but not with full-length BP180. Toyonaga et al. determined that cleavage within both the C-terminal region and NC16A domain plays a role in exposure of neoepitopes on the 15th collagenous domain of BP180.
Takashi Hashimoto   +2 more
openaire   +2 more sources

Author response: Type XVII collagen coordinates proliferation in the interfollicular epidermis

open access: gold, 2017
Mika Watanabe   +15 more
openaire   +2 more sources

Epidermolysis Bullosa—A Kindler Syndrome Case Report and Short Literature Review

open access: yesClinics and Practice, 2023
Introduction: Epidermolysis bullosa (EB) represents a group of rare disorders, genetically determined, characterized by skin fragility, blister formation and erosions due to minimal trauma.
Bogdan Ioan Stefanescu   +6 more
doaj   +1 more source

Junctional Epidermolysis Bullosa: Allelic Heterogeneity and Mutation Stratification for Precision Medicine

open access: yesFrontiers in Medicine, 2019
Junctional epidermolysis bullosa (JEB) is a hereditary blistering disease caused by reduced dermal-epidermal adhesion due to deficiencies of one of the proteins, laminin-332, type XVII collagen, integrin α6β4 or integrin α3. Significant progress has been
Irina Condrat   +4 more
doaj   +1 more source

Diagnosing Paraproteinemic Keratopathy: A Case Report

open access: yesCase Reports in Ophthalmology, 2021
A 65-year-old man presented with bilateral, painless, progressive blurring of vision over 9 years. Slit-lamp examination revealed bilateral subepithelial corneal opacities in clusters located at the mid-periphery.
Eugenie Mok   +3 more
doaj   +1 more source

Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid

open access: yesFrontiers in Immunology, 2021
The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with
Xiaoyan Zhang   +4 more
doaj   +1 more source

Fibroblast and keratinocyte gene expression following exposure to the extracts of holy basil plant (Ocimum tenuiflorum), malabar nut plant (Justicia adhatoda), and emblic myrobalan plant (Phyllanthus emblica)

open access: yesData in Brief, 2018
This data article provides gene expression profiles, determined by using real-time PCR, of fibroblasts and keratinocytes treated with 0.01% and 0.001% extracts of holy basil plant (Ocimum tenuiflorum), sri lankan local name “maduruthala”, 0.1% and 0.01 ...
Takao Someya   +5 more
doaj   +1 more source

Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2

open access: yesFrontiers in Immunology, 2018
Bullous pemphigoid (BP), the most frequent autoimmune bullous disorder, is a paradigmatic autoantibody-mediated disease associated with autoantibodies against BP180 (type XVII collagen, Col17).
Christian M. Karsten   +13 more
doaj   +1 more source

Recombinant Type XVII Collagen Inhibits EGFR/MAPK/AP-1 and Activates TGF-β/Smad Signaling to Enhance Collagen Secretion and Reduce Photoaging

open access: yesCosmetics
Studies have consistently shown that long-wave ultraviolet A (UVA) radiation triggers skin photoaging, which is evident as reduced elasticity, a loss of firmness, and signs of aging.
Ying He   +6 more
doaj   +1 more source

Autoimmunity against laminin 332

open access: yesFrontiers in Immunology, 2023
Laminin 332 is a heterotrimeric structural protein of the basal membrane zone (BMZ) of the skin and adjacent mucosal tissues. The importance of laminin 332 for the structural integrity of the BMZ is demonstrated by mutations in any of the three genes ...
Sabrina Patzelt   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy